Pages that link to "Q33713689"
Jump to navigation
Jump to search
The following pages link to Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. (Q33713689):
Displaying 50 items.
- Oligonucleotide therapeutic approaches for Huntington disease (Q22306293) (← links)
- A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression (Q24620388) (← links)
- Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease (Q24626259) (← links)
- Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice (Q24628256) (← links)
- Huntington's disease: the past, present, and future search for disease modifiers (Q26830039) (← links)
- Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy (Q26849677) (← links)
- Mechanisms of RNA-induced toxicity in CAG repeat disorders (Q26860030) (← links)
- Pluripotent stem cells models for Huntington's disease: prospects and challenges (Q26860151) (← links)
- Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. (Q27005950) (← links)
- Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain (Q27317421) (← links)
- Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells (Q27324212) (← links)
- Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice (Q27324749) (← links)
- Current prospects for RNA interference-based therapies (Q28235733) (← links)
- Epigenetic mechanisms of neurodegeneration in Huntington's disease (Q28297936) (← links)
- p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease (Q28386238) (← links)
- Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients (Q28542911) (← links)
- Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study (Q28546047) (← links)
- Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression (Q30438915) (← links)
- Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease (Q30493159) (← links)
- A fully humanized transgenic mouse model of Huntington disease. (Q30537951) (← links)
- Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis (Q30848992) (← links)
- Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. (Q33507519) (← links)
- Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells (Q33594270) (← links)
- Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs (Q33632395) (← links)
- Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing (Q33752590) (← links)
- Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression (Q33755845) (← links)
- Huntington's disease: from molecular pathogenesis to clinical treatment (Q33773061) (← links)
- Oligonucleotide-based strategies to combat polyglutamine diseases (Q33791247) (← links)
- Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury (Q33836761) (← links)
- Efficient Allele-Specific Targeting of LRRK2 R1441 Mutations Mediated by RNAi (Q33945342) (← links)
- Rhes suppression enhances disease phenotypes in Huntington's disease mice (Q34071922) (← links)
- Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice (Q34159111) (← links)
- An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases (Q34187525) (← links)
- Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin (Q34221351) (← links)
- RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1 (Q34235172) (← links)
- Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. (Q34283652) (← links)
- Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy (Q34397572) (← links)
- Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. (Q34463222) (← links)
- Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells (Q34469493) (← links)
- Mesenchymal stem cells for the treatment of neurodegenerative disease. (Q34473474) (← links)
- Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism (Q34492631) (← links)
- Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia (Q34499502) (← links)
- Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain (Q34579818) (← links)
- Antisense therapy in neurology (Q34608717) (← links)
- RNAi medicine for the brain: progresses and challenges. (Q34982838) (← links)
- Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective (Q35024695) (← links)
- Gene therapy in mouse models of huntington disease. (Q35090208) (← links)
- RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. (Q35156007) (← links)
- Splice isoform-specific suppression of the CaV2.1 variant underlying spinocerebellar ataxia type 6 (Q35203559) (← links)
- A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity (Q35214858) (← links)